CD56、CD117表达水平与来那度胺治疗多发性骨髓瘤疗效的相关性分析

目的:探讨CD56、CD117的表达水平与来那度胺治疗多发性骨髓瘤疗效的相关性,为预测来那度胺治疗多发性骨髓瘤的疗效提供参考依据。方法:将我院2016年12月至2019年3月收治的多发性骨髓瘤患者64例,均给予来那度胺联合小剂量地塞米松治疗,所有患者根据疗效分为完全缓解(CR)、非常好的部分缓解(VGPR)、部分缓解(PR)、疾病稳定(SD)、疾病进展(PD),并且采用门诊、电话、住院等随访方式定期随访。采用流式细胞仪测定所有患者入院治疗前一天的CD56、CD117的表达水平,分析CD56、CD117表达与患者病理特征以及来那度胺疗效的相关性。结果:CD56、CD117的表达水平与多发性骨髓瘤患者的轻链分型、M蛋白分型、临床分型显著相关,与性别无关。来那度胺治疗多发性骨髓瘤的64例患者中,有效例数53例,总有效率为83%;其有效组患者中,CD56、CD117的阳性率分别为56.6%、35.8%,显著高于无效组患者(18.2%、9.1%)(P<0.05)。结论:多发性骨髓瘤患者CD56、CD117均呈现高表达的状态,其表达与患者的临床分期、M蛋白类型、轻链重链类型及来那度胺治疗的疗效有显著相关性。

Expression of CD56 and CD117 and Its Correlation with the Efficacy of Lenalidomide in the Treatment of Multiple Myeloma

ABSTRACT Objective: To explore the correlation between the expression of CD56 and CD117 and the efficacy of lenadomide in the treatment of multiple myeloma, and provide references for predicting the efficacy of lenadomide in the treatment of multiple myeloma. Methods: Sixty-four patients with multiple myeloma admitted to our hospital from December 2016 to March 2019 were treated with lenalidomide combined with low-dose dexamethasone. All patients were divided into four groups according to the therapeutic effect, including complete remission (CR), very good partial remission (VGPR), partial remission (PR), disease stability (SD), disease progression (PD), and follow-up methods such as outpatient, telephone and hospitalization were used for regular follow-up. Flow cytometry was used to detect the expression of CD56 and CD117 on plasma cell surface in all patients one day before admission. The correlation between the expression of CD56 and CD117 and the pathological characteristics of patients include the efficacy of lenalidomide was analyzed. Results: The expression of CD56 and CD117 were significantly correlated with light chain typing, M protein typing and clinical typing in patients with multiple myeloma, but showed no correlation with gender. Among 64 patients with multiple myeloma treated with lenalidomide, 53 were effective, with a total effective rate of 83%. The positive rates of CD56 and CD117 in the effective group were 56.6% and 35.8%, respectively, which were significantly higher than those in the ineffective group (18.2% and 9.1%) (P < 0.05). Conclusion: CD56 and CD117 were highly expressed in patients with multiple myeloma, which were significantly correlated with the clinical stage, M protein type, light chain heavy chain type and the efficacy of lenalidomide therapy.